Close
Smartlab Europe
Achema middle east

Serbia gets shipment of AstraZeneca COVID-19 vaccine made in India

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach

In order to broaden its portfolio in imaging and...

UK Clinical Trial Regulatory Reforms Aim to Boost Research

A number of regulatory changes have been released by...

The Future of Vertigo Diagnostic and Treatment Options in 2026

Vertigo is an uncomfortable sensation in which you feel...
- Advertisement -

A shipment of 150,000 COVID-19 vaccines developed by AstraZeneca and Oxford University arrived at Belgrade airport on Sunday, making Serbia the first country in the Western Balkan region to receive supplies of the shot.

The vaccines, which arrived on a Turkish Airlines plane from Istanbul, were produced in India, said President Aleksandar Vucic, who came to the airport to meet the shipment.

Vucic said the price of the vaccine was “very good as both AstraZeneca and Oxford gave up their profits”. He added that another shipment of 150,000 vaccines is expected in 12 weeks time.

“This vaccine was developed by a young team at the Oxford University which also included young people from Serbia,” British ambassador Sian MacLeod told reporters at the airport.

More than 730,000 people, or a little over 10 per cent of the population, have been vaccinated against COVID-19 since December with one or two doses of the vaccines available in Serbia.

Under the state vaccination programme, Serbians have been able to choose between shots from Pfizer-BioNTech , China’s Sinopharm or Russia’s Sputnik V.

Latest stories

Related stories

Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach

In order to broaden its portfolio in imaging and...

UK Clinical Trial Regulatory Reforms Aim to Boost Research

A number of regulatory changes have been released by...

The Future of Vertigo Diagnostic and Treatment Options in 2026

Vertigo is an uncomfortable sensation in which you feel...

Why Medical Conferences Matter in Modern Healthcare

The physical gathering of healthcare professionals, researchers, and industry...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »